A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipient/Overt Diabetic Nephropathy

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipient/Overt Diabetic Nephropathy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Aliskiren; Irbesartan
  • Indications Diabetic nephropathies; Hypertension; Proteinuria; Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 13 Oct 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 01 Oct 2009 Results were published in Diabetes Care.
    • 07 Sep 2008 Results have been presented at EASD 2008. Primary endpoint met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top